Market Overview:
Cutaneous mastocytosis is a rare skin disorder that results in the accumulation of mast cells in the skin. These cells release histamine and other chemicals, which can cause itching, flushing, hives, and other symptoms. The global cutaneous mastocytosis treatment market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth of this market is mainly driven by increasing awareness about cutaneous mastocytosis and its treatments among healthcare professionals and patients. Additionally, increasing research on new therapies for cutaneous mastocytosis is also contributing to the growth of this market.
Product Definition:
Cutaneous mastocytosis is a rare skin condition that causes too many mast cells to form in the skin. Mast cells are important in the body's immune system. They help fight infection and inflammation. Cutaneous mastocytosis can cause red, itchy patches on the skin, as well as swelling, flushing, and other symptoms.
Cutaneous mastocytosis may not require treatment if it doesn't bother you or if you only have a few small patches of affected skin. If your symptoms are bothersome or getting worse, your doctor may prescribe medications such as antihistamines or corticosteroids to help relieve them.
Antihistamines:
Antihistamines are used to treat itching. They work by decreasing the histamine response. The most commonly used antihistamines are Loratadine (Claritin), fexofenadine (Allerga), diphenhydramine (Benadryl).
Global Antihistamines, it's usage.
Corticosteroids:
Corticosteroids are the group of drugs whose action is to reduce inflammation by suppressing the release of cytokines by immune cells. Corticosteroid treatment for CMMT includes two types: topical and oral. Topical corticosteroids are used in most cases, but oral steroids may be prescribed if there is a risk of infection at the site of injection or if other precautions are taken.
Application Insights:
The others application segment held the largest share of cutaneous mastocytosis treatment market owing to high prevalence of the disease. The application includes oral and injectable therapies, phototherapy, and other applications such as skin-bonded devices and surgery. Oral medications are generally preferred over injectable or topical therapies due to their availability in a pill form that can be taken by mouth daily as required by patients.
Oral medications include cromolyn sodium ( Cromolyn) which is an anti-inflammatory agent used for treating nasal congestion due to allergies or colds. It also reduces swelling & itching caused by insect bites & stings, sunburn, minor burns, eczema (dermatitis), allergic rhinitis (hay fever), asthma attacks & other symptoms related to asthma including shortness of breath during exercise or activity along with improvement in lung function tests among adults who have been diagnosed with cutaneous mastocytosis previously treated using antihistamines only.
Regional Analysis:
North America dominated the global cutaneous mastocytosis treatment market in 2017. This can be attributed to the presence of a large number of players, high adoption rate for new technologies, and increasing government initiatives & funding for CMT research. For instance, in 2014-2015 academic year, mast cell leukemia received a grant of USD X million from MAST (Magical Aids Science and Technology Foundation) which is an organization that provides funds to researchers working on HIV/AIDS and cancer. The fund provided by this foundation was used to study Mast Cell-Leukemia Treatment using ephinephrine.
Asia Pacific is expected to grow at the fastest pace during the forecast period due to factors such as improving healthcare infrastructure & availability; rising disposable income; increase awareness about early diagnosis; rise in patient pool suffering from skin disorders coupled with growing medical tourism industry especially for diseases like leprosy.
Growth Factors:
- Increasing incidence of cutaneous mastocytosis
- Growing awareness about cutaneous mastocytosis and its treatment options
- Rising demand for better and more effective treatments for cutaneous mastocytosis
- Availability of new and innovative therapies for the treatment of cutaneous mastocytosis
- Growing number of clinical studies on the efficacy and safety of various treatments for cutaneous mastocytosis
Scope Of The Report
Report Attributes
Report Details
Report Title
Cutaneous Mastocytosis Treatment Market Research Report
By Type
Antihistamines, Corticosteroids, Mast Cell Stabilizers, Sympathomimetic Agents (Ephinephrine), Photochemotherapy
By Application
Hospitals, Clinic, Others
By Companies
Novartis AG, Mylan NV, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sanofi S.A., Johnson & Johnson, Bayer AG, Mallinckrodt Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
158
Number of Tables & Figures
111
Customization Available
Yes, the report can be customized as per your need.
Global Cutaneous Mastocytosis Treatment Market Report Segments:
The global Cutaneous Mastocytosis Treatment market is segmented on the basis of:
Types
Antihistamines, Corticosteroids, Mast Cell Stabilizers, Sympathomimetic Agents (Ephinephrine), Photochemotherapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis AG
- Mylan NV
- Teva Pharmaceutical Industries Ltd.
- Bausch Health Companies Inc.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Sanofi S.A.
- Johnson & Johnson
- Bayer AG
- Mallinckrodt Pharmaceuticals
Highlights of The Cutaneous Mastocytosis Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antihistamines
- Corticosteroids
- Mast Cell Stabilizers
- Sympathomimetic Agents (Ephinephrine)
- Photochemotherapy
- By Application:
- Hospitals
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cutaneous Mastocytosis Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cutaneous mastocytosis treatment typically includes medications to control the symptoms and/or a skin transplant.
Some of the major players in the cutaneous mastocytosis treatment market are Novartis AG, Mylan NV, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sanofi S.A., Johnson & Johnson, Bayer AG, Mallinckrodt Pharmaceuticals.
The cutaneous mastocytosis treatment market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cutaneous Mastocytosis Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cutaneous Mastocytosis Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cutaneous Mastocytosis Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cutaneous Mastocytosis Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cutaneous Mastocytosis Treatment Market Size & Forecast, 2018-2028
4.5.1 Cutaneous Mastocytosis Treatment Market Size and Y-o-Y Growth
4.5.2 Cutaneous Mastocytosis Treatment Market Absolute $ Opportunity
Chapter 5 Global Cutaneous Mastocytosis Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Cutaneous Mastocytosis Treatment Market Size Forecast by Type
5.2.1 Antihistamines
5.2.2 Corticosteroids
5.2.3 Mast Cell Stabilizers
5.2.4 Sympathomimetic Agents (Ephinephrine)
5.2.5 Photochemotherapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Cutaneous Mastocytosis Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Cutaneous Mastocytosis Treatment Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cutaneous Mastocytosis Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cutaneous Mastocytosis Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Cutaneous Mastocytosis Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Cutaneous Mastocytosis Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Cutaneous Mastocytosis Treatment Market Size Forecast by Type
9.6.1 Antihistamines
9.6.2 Corticosteroids
9.6.3 Mast Cell Stabilizers
9.6.4 Sympathomimetic Agents (Ephinephrine)
9.6.5 Photochemotherapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Cutaneous Mastocytosis Treatment Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Cutaneous Mastocytosis Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Cutaneous Mastocytosis Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Cutaneous Mastocytosis Treatment Market Size Forecast by Type
10.6.1 Antihistamines
10.6.2 Corticosteroids
10.6.3 Mast Cell Stabilizers
10.6.4 Sympathomimetic Agents (Ephinephrine)
10.6.5 Photochemotherapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Cutaneous Mastocytosis Treatment Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Cutaneous Mastocytosis Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Cutaneous Mastocytosis Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Cutaneous Mastocytosis Treatment Market Size Forecast by Type
11.6.1 Antihistamines
11.6.2 Corticosteroids
11.6.3 Mast Cell Stabilizers
11.6.4 Sympathomimetic Agents (Ephinephrine)
11.6.5 Photochemotherapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Cutaneous Mastocytosis Treatment Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Cutaneous Mastocytosis Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Cutaneous Mastocytosis Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Cutaneous Mastocytosis Treatment Market Size Forecast by Type
12.6.1 Antihistamines
12.6.2 Corticosteroids
12.6.3 Mast Cell Stabilizers
12.6.4 Sympathomimetic Agents (Ephinephrine)
12.6.5 Photochemotherapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Cutaneous Mastocytosis Treatment Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Cutaneous Mastocytosis Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Cutaneous Mastocytosis Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Cutaneous Mastocytosis Treatment Market Size Forecast by Type
13.6.1 Antihistamines
13.6.2 Corticosteroids
13.6.3 Mast Cell Stabilizers
13.6.4 Sympathomimetic Agents (Ephinephrine)
13.6.5 Photochemotherapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Cutaneous Mastocytosis Treatment Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cutaneous Mastocytosis Treatment Market: Competitive Dashboard
14.2 Global Cutaneous Mastocytosis Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis AG
14.3.2 Mylan NV
14.3.3 Teva Pharmaceutical Industries Ltd.
14.3.4 Bausch Health Companies Inc.
14.3.5 Pfizer Inc.
14.3.6 Teva Pharmaceutical Industries Ltd.
14.3.7 Sanofi S.A.
14.3.8 Johnson & Johnson
14.3.9 Bayer AG
14.3.10 Mallinckrodt Pharmaceuticals
